STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+ azacitidine in higher risk MDS and CMML-2
AM Zeidan, A Giagounidis, MA Sekeres, Z Xiao… - Future …, 2022 - Future Medicine
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic
leukemia (CMML) unfit for hematopoietic stem cell transplantation have poor outcomes …
leukemia (CMML) unfit for hematopoietic stem cell transplantation have poor outcomes …
Red blood cell transfusion in myelodysplastic syndromes: A systematic review
S Kaka, A Jahangirnia, N Beauregard… - Transfusion …, 2022 - Wiley Online Library
Patients with myelodysplastic syndrome (MDS) frequently receive red blood cell (RBC)
transfusions for anaemia resulting from ineffective erythropoiesis. While RBC transfusions …
transfusions for anaemia resulting from ineffective erythropoiesis. While RBC transfusions …
[HTML][HTML] A systematic literature review of the relationship between serum ferritin and outcomes in myelodysplastic syndromes
EN Oliva, K Huey, S Deshpande, M Turner… - Journal of Clinical …, 2022 - mdpi.com
Anemia is the most common form of cytopenia in patients with myelodysplastic syndromes
(MDS), who require chronic red blood cell transfusions and may present high serum ferritin …
(MDS), who require chronic red blood cell transfusions and may present high serum ferritin …
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes
AE DeZern, G Binder, S Rizvi, FA Corvino… - Leukemia & …, 2017 - Taylor & Francis
Transfusion dependence (TD) among myelodysplastic syndromes (MDS) patients negatively
impacts survival and health-related quality of life. We evaluated cost patterns of MDS care …
impacts survival and health-related quality of life. We evaluated cost patterns of MDS care …
[HTML][HTML] Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere
AT Gerds, MA Sekeres - Leukemia & lymphoma, 2014 - Taylor & Francis
Anemia has long been one of the defining characteristics of the myelodysplastic syndromes
(MDS), and is present in over 50% of patients at the time of diagnosis. This clinical finding …
(MDS), and is present in over 50% of patients at the time of diagnosis. This clinical finding …
Análise da população de pacientes com neoplasia mielodisplásica de baixo risco atendida no Hospital de Clínicas de Porto Alegre
CK Weber - 2024 - lume.ufrgs.br
Introdução: A Neoplasia Mielodisplásica (NMD) compreende um espectro de uma doença
clonal da medula óssea associada à hematopoese ineficaz, manifestando-se em …
clonal da medula óssea associada à hematopoese ineficaz, manifestando-se em …
[HTML][HTML] Advances and perspectives on cellular therapy in acquired bone marrow failure diseases
XS Sun, X Liu, KL Xu, A Chen, WB Rybka… - World Journal of …, 2016 - wjgnet.com
Acquired bone marrow failure diseases (ABMFD) are a class of hematopoietic stem cell
diseases with a commonality of non-inherited disruption of hematopoiesis that results in …
diseases with a commonality of non-inherited disruption of hematopoiesis that results in …